Study identifies common skin bacterium as previously unknown culprit behind itch

A small Ger­man biotech at­tempt­ing to crack in­to the gene edit­ing field with an evolved ap­proach to a decades-old re­search in­ter­est has nabbed for­mer Ho­mol­o­gy

Ex­elix­is is buy­ing in­to a can­cer drug can­di­date dis­cov­ered by gen­er­a­tive AI from In­sil­i­co Med­i­cine, the two com­pa­nies an­nounced Tues­day. The Bay Area can­cer com­pa­ny